Santhera Pharmaceuticals Holding AG
SANN
Rankning i aktier
#16593
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company,... Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company’s lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.
Aktiekurs
$17.23
Marknadsvärde
$263.68M
Förändring (1 dag)
-4.18%
Förändring (1 år)
38.54%
Land
CH
Handel Santhera Pharmaceuticals Holding AG (SANN)
Kategori
Healthcare
Aktiekurshistorik för Santhera Pharmaceuticals Holding AG (SANN)
Högsta slutkurs: $18.92 den 2026-10-01
Lägsta slutkurs: $44.13 den 2014-03-01
Lägsta slutkurs: $44.13 den 2014-03-01
Aktiekurshistorik för Santhera Pharmaceuticals Holding AG från 2014 till 2026
Årlig aktiekursutveckling
| År | Prestanda |
|---|---|
| 2026 (TTM) | 22.24% |
| 2025 | 42.98% |
| 2024 | -6.16% |
| 2023 | 41.12% |
| 2022 | -43.82% |
| 2021 | -53.14% |
| 2020 | -74.39% |
| 2019 | -17.31% |
| 2018 | -49.89% |
| 2017 | -38.99% |
| 2016 | -48.52% |
| 2015 | -16.32% |
| 2014 | 0.00% |
Aktiekurs för liknande företag eller konkurrenter
| Företag | Aktiekurs | Förändring 1år% | Land |
|---|---|---|---|
| $536.13 | 25.72% |
US
|
|
| $200.12 | 645.31% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $880.01 | 8.09% |
NL
|
